WeVote
Log In

Bill

JA

Bill

A 5571

Prohibits pre-approval or precertification of medical tests, procedures and prescription drugs covered under health benefits or prescription drug benefits plans.

2024-2025 Regular Session Introduced by John Azzariti and 2 co-sponsors

New Jersey bill prohibits health insurers from requiring pre-approval of covered medical tests, procedures, and drugs, eliminating authorization delays but potentially increasing costs and removing utilization safeguards.

Introduced in the Assembly, Referred to Assembly Financial Institutions and Insurance Committee
#pharmaceutic #pubempbene
0
WeVote Research Nonpartisan
Bill Summary · A 5571

Legislative bill overview

Bill A 5571 would prohibit health insurance plans and prescription drug plans from requiring pre-approval or precertification before patients can access covered medical tests, procedures, and prescription drugs. This eliminates a common insurance practice where insurers review and approve treatments before they're administered or dispensed.

Why is this important

Pre-authorization requirements can delay critical medical care, particularly in urgent or time-sensitive situations, and create administrative burdens for patients and providers. Conversely, these requirements help insurers manage costs and prevent unnecessary procedures. The bill directly affects how healthcare decisions are made and who bears financial risk for medical services.

Potential points of contention

  • Cost implications: Removing pre-authorization safeguards could increase insurance claim denials and out-of-pocket costs shift to patients, or increase premiums if insurers cannot manage utilization
  • Provider workflow disruption: Eliminates a coordination mechanism between insurers and providers; may create confusion about coverage and payment responsibility
  • Medical appropriateness: Pre-auth processes, while sometimes delayed, prevent some medically unnecessary or potentially harmful treatments; removal could allow inappropriate care without insurer review
  • Scope uncertainty: Unclear whether emergency situations, experimental treatments, or out-of-network care would be affected differently
  • Interstate inconsistency: New Jersey acting alone could create competitive disadvantages for state insurers or challenges for multi-state plans

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.